|
1
|
Bach DH, Lee SK and Sood AK: Circular RNAs
in cancer. Mol Ther Nucleic Acids. 16:118–129. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanger HL, Klotz G, Riesner D, Gross HJ
and Kleinschmidt AK: Viroids are single-stranded covalently closed
circular RNA molecules existing as highly base-paired rod-like
structures. Proc Natl Acad Sci USA. 73:3852–3856. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nigro JM, Cho KR, Fearon ER, Kern SE,
Ruppert JM, Oliner JD, Kinzler KW and Vogelstein B: Scrambled
exons. Cell. 64:607–613. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barrett SP and Salzman J: Circular RNAs:
Analysis, expression and potential functions. Development.
143:1838–1847. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu N, Chen S, Liu Y, Li W, Liu Z, Bian X,
Ling C and Jiang M: Profiles and bioinformatics analysis of
differentially expressed circrnas in taxol-resistant non-small cell
lung cancer cells. Cell Physiol Biochem. 48:2046–2060. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou R, Chen KK, Zhang J, Xiao B, Huang Z,
Ju C, Sun J, Zhang F, Lv XB and Huang G: The decade of exosomal
long RNA species: An emerging cancer antagonist. Mol Cancer.
17:752018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Solassol I, Pinguet F and Quantin X: FDA-
and EMA-Approved tyrosine kinase inhibitors in advanced
EGFR-Mutated non-small cell lung cancer: Safety, tolerability,
plasma concentration monitoring, and management. Biomolecules.
9:6682019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lei K, Bai H, Wei Z, Xie C, Wang J, Li J
and Chen Q: The mechanism and function of circular RNAs in human
diseases. Exp Cell Res. 368:147–158. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiong DD, Dang YW, Lin P, Wen DY, He RQ,
Luo DZ, Feng ZB and Chen G: A circRNA-miRNA-mRNA network
identification for exploring underlying pathogenesis and therapy
strategy of hepatocellular carcinoma. J Transl Med. 16:2202018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bayani J, Kuzmanov U, Saraon P, Fung WA,
Soosaipillai A, Squire JA and Diamandis EP: Copy number and
expression alterations of miRNAs in the ovarian cancer cell line
OVCAR-3: Impact on kallikrein 6 protein expression. Clin Chem.
59:296–305. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Wei Y, Yan Y, Wang H, Yang J,
Zheng Z, Zha J, Bo P, Tang Y, Guo X, et al: CircDOCK1 suppresses
cell apoptosis via inhibition of miR196a5p by targeting BIRC3 in
OSCC. Oncol Rep. 39:951–966. 2018.PubMed/NCBI
|
|
14
|
Li X, Yang L and Chen LL: The biogenesis,
functions, and challenges of circular RNAs. Mol Cell. 71:428–442.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo JU, Agarwal V, Guo H and Bartel DP:
Expanded identification and characterization of mammalian circular
RNAs. Genome Biol. 15:4092014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kristensen LS, Hansen TB, Venø MT and
Kjems J: Circular RNAs in cancer: Opportunities and challenges in
the field. Oncogene. 37:555–565. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du WW, Yang W, Liu E, Yang Z, Dhaliwal P
and Yang BB: Foxo3 circular RNA retards cell cycle progression via
forming ternary complexes with p21 and CDK2. Nucleic Acids Res.
44:2846–2858. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Conn VM, Hugouvieux V, Nayak A, Conos SA,
Capovilla G, Cildir G, Jourdain A, Tergaonkar V, Schmid M, Zubieta
C and Conn SJ: A circRNA from SEPALLATA3 regulates splicing of its
cognate mRNA through R-loop formation. Nat Plants. 3:170532017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong R, Zhang XO, Zhang Y, Ma XK, Chen LL
and Yang L: CircRNA-derived pseudogenes. Cell Res. 26:747–750.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jeck WR, Sorrentino JA, Wang K, Slevin MK,
Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are
abundant, conserved, and associated with ALU repeats. RNA.
19:141–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Zhang XO, Chen T, Xiang JF, Yin
QF, Xing YH, Zhu S, Yang L and Chen LL: Circular intronic long
noncoding RNAs. Mol Cell. 51:792–806. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abdelmohsen K, Panda AC, Munk R,
Grammatikakis I, Dudekula DB, De S, Kim J, Noh JH, Kim KM,
Martindale JL and Gorospe M: Identification of HuR target circular
RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA
Biol. 14:361–369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holdt LM, Stahringer A, Sass K, Pichler G,
Kulak NA, Wilfert W, Kohlmaier A, Herbst A, Northoff BH, Nicolaou
A, et al: Circular non-coding RNA ANRIL modulates ribosomal RNA
maturation and atherosclerosis in humans. Nat Commun. 7:124292016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pamudurti NR, Bartok O, Jens M,
Ashwal-Fluss R, Stottmeister C, Ruhe L, Hanan M, Wyler E,
Perez-Hernandez D, Ramberger E, et al: Translation of CircRNAs. Mol
Cell. 66:9–21.e7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang C, Xie Y, Yu T, Liu N, Wang Z,
Woolsey RJ, Tang Y, Zhang X, Qin W, Zhang Y, et al:
m6A-dependent biogenesis of circular RNAs in male germ
cells. Cell Res. 30:211–228. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Legnini I, Di Timoteo G, Rossi F, Morlando
M, Briganti F, Sthandier O, Fatica A, Santini T, Andronache A, Wade
M, et al: Circ-ZNF609 Is a Circular RNA that can be translated and
functions in myogenesis. Mol Cell. 66:22–37.e9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thomas H and Coley HM: Overcoming
multidrug resistance in cancer: An update on the clinical strategy
of inhibiting p-glycoprotein. Cancer Control. 10:159–165. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shapira A, Livney YD, Broxterman HJ and
Assaraf YG: Nanomedicine for targeted cancer therapy: Towards the
overcoming of drug resistance. Drug Resist Updat. 14:150–163. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hashida S, Soh J, Toyooka S, Furukawa M,
Shien K, Yamamoto H, Asano H, Tsukuda K, Hagiwara K and Miyoshi S:
Presence of the minor EGFR T790M mutation is associated with
drug-sensitive EGFR mutations in lung adenocarcinoma patients.
Oncol Rep. 32:145–152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shaw AT, Yeap BY, Solomon BJ, Riely GJ,
Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, et
al: Effect of crizotinib on overall survival in patients with
advanced non-small-cell lung cancer harbouring ALK gene
rearrangement: A retrospective analysis. Lancet Oncol.
12:1004–1012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zakharenko A, Dyrkheeva N and Lavrik O:
Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1
inhibition for improved anticancer activity. Med Res Rev.
39:1427–1441. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Usanova S, Piée-Staffa A, Sied U, Thomale
J, Schneider A, Kaina B and Köberle B: Cisplatin sensitivity of
testis tumour cells is due to deficiency in interstrand-crosslink
repair and low ERCC1-XPF expression. Mol Cancer. 9:2482010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan S, el-Deiry WS, Bae I, Freeman J,
Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW and O'Connor
PM: p53 gene mutations are associated with decreased sensitivity of
human lymphoma cells to DNA damaging agents. Cancer Res.
54:5824–5830. 1994.PubMed/NCBI
|
|
37
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
White E, Mehnert JM and Chan CS:
Autophagy, metabolism, and cancer. Clin Cancer Res. 21:5037–5046.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
White E and DiPaola RS: The double-edged
sword of autophagy modulation in cancer. Clin Cancer Res.
15:5308–5316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sasaki K, Tsuno NH, Sunami E, Tsurita G,
Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, et al:
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on
colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arnold D, Lueza B, Douillard JY, Peeters
M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP,
Tabernero J, et al: Prognostic and predictive value of primary
tumour side in patients with RAS wild-type metastatic colorectal
cancer treated with chemotherapy and EGFR directed antibodies in
six randomized trials. Ann Oncol. 28:1713–1729. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fuchs BC, Fujii T, Dorfman JD, Goodwin JM,
Zhu AX, Lanuti M and Tanabe KK: Epithelial-to-mesenchymal
transition and integrin-linked kinase mediate sensitivity to
epidermal growth factor receptor inhibition in human hepatoma
cells. Cancer Res. 68:2391–2399. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hoyt K, Castaneda B, Zhang M, Nigwekar P,
di Sant'agnese PA, Joseph JV, Strang J, Rubens DJ and Parker KJ:
Tissue elasticity properties as biomarkers for prostate cancer.
Cancer Biomark. 4:213–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wilson TR, Fridlyand J, Yan Y, Penuel E,
Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al:
Widespread potential for growth-factor-driven resistance to
anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Safaei R, Larson BJ, Cheng TC, Gibson MA,
Otani S, Naerdemann W and Howell SB: Abnormal lysosomal trafficking
and enhanced exosomal export of cisplatin in drug-resistant human
ovarian carcinoma cells. Mol Cancer Ther. 4:1595–1604. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu T, Chen G, Sun D, Lei M, Li Y, Zhou C,
Li X, Xue W, Wang H, Liu C and Xu J: Exosomes containing miR-21
transfer the characteristic of cisplatin resistance by targeting
PTEN and PDCD4 in oral squamous cell carcinoma. Acta Biochim
Biophys Sin (Shanghai). 49:808–816. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nathanson DA, Gini B, Mottahedeh J,
Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et
al: Targeted therapy resistance mediated by dynamic regulation of
extrachromosomal mutant EGFR DNA. Science. 343:72–76. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hsu HH, Kuo WW, Shih HN, Cheng SF, Yang
CK, Chen MC, Tu CC, Viswanadha VP, Liao PH and Huang CY: FOXC1
regulation of miR-31-5p confers oxaliplatin resistance by targeting
LATS2 in colorectal cancer. Cancers (Basel). 11:15762019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu X, Chen X, Xu M, Liu X, Pan B, Qin J,
Xu T, Zeng K, Pan Y, He B, et al: miR-375-3p suppresses
tumorigenesis and partially reverses chemoresistance by targeting
YAP1 and SP1 in colorectal cancer cells. Aging (Albany NY).
11:7357–7385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang X, Li Z, Zhang Q, Wang W, Li B, Wang
L, Xu Z, Zeng A, Zhang X, Zhang X, et al: Circular RNA AKT3
upregulates PIK3R1 to enhance cisplatin resistance in gastric
cancer via miR-198 suppression. Mol Cancer. 18:712019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yan L, Liu G, Cao H, Zhang H and Shao F:
Hsa_circ_0035483 sponges hsa-miR-335 to promote the
gemcitabine-resistance of human renal cancer cells by autophagy
regulation. Biochem Biophys Res Commun. 519:172–178. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lapa RML, Barros-Filho MC, Marchi FA,
Domingues MAC, de Carvalho GB, Drigo SA, Kowalski LP and Rogatto
SR: Integrated miRNA and mRNA expression analysis uncovers drug
targets in laryngeal squamous cell carcinoma patients. Oral Oncol.
93:76–84. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen D, Bao C, Zhao F, Yu H, Zhong G, Xu L
and Yan S: Exploring specific miRNA-mRNA axes with relationship to
taxanes-resistance in breast cancer. Front Oncol. 10:13972020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kong F, He S, Shen X, Li L, Fang J and
Lian M: Integrated analysis of different mRNA and miRNA profiles in
human hypopharyngeal squamous cell carcinoma sensitive and
resistant to chemotherapy. Neoplasma. 67:473–483. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Guarnerio J, Bezzi M, Jeong JC, Paffenholz
SV, Berry K, Naldini MM, Lo-Coco F, Tay Y, Beck AH and Pandolfi PP:
Oncogenic role of Fusion-circRNAs Derived from cancer-associated
chromosomal translocations. Cell. 165:289–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dos Santos GA, Kats L and Pandolfi PP:
Synergy against PML-RARa: Targeting transcription, proteolysis,
differentiation, and self-renewal in acute promyelocytic leukemia.
J Exp Med. 210:2793–2802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pan Y, Lou J, Wang H, An N, Chen H, Zhang
Q and Du X: CircBA9.3 supports the survival of leukaemic cells by
up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol
Dis. 73:38–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shi Q, Huo N, Wang X, Yang S, Wang J and
Zhang T: Exosomes from oral tissue stem cells: Biological effects
and applications. Cell Biosci. 10:1082020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhao Z, Ji M, Wang Q, He N and Li Y:
Circular RNA Cdr1as Upregulates SCAI to suppress cisplatin
resistance in ovarian cancer via miR-1270 suppression. Mol Ther
Nucleic Acids. 18:24–33. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Luo Y and Gui R: Circulating Exosomal
circMYC is associated with the recurrence and bortezomib resistance
in patients with multiple myeloma. Turk J Haematol. 37:248–262.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ding C, Yi X, Wu X, Bu X, Wang D, Wu Z,
Zhang G, Gu J and Kang D: Exosome-mediated transfer of circRNA
CircNFIX enhances temozolomide resistance in glioma. Cancer Lett.
479:1–12. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Anantha RW, Simhadri S, Foo TK, Miao S,
Liu J, Shen Z, Ganesan S and Xia B: Functional and mutational
landscapes of BRCA1 for homology-directed repair and therapy
resistance. Elife. 6:e213502017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang X, Fraser M, Abedini MR, Bai T and
Tsang BK: Regulation of apoptosis-inducing factor-mediated,
cisplatin-induced apoptosis by Akt. Br J Cancer. 98:803–808. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shang J, Chen WM, Liu S, Wang ZH, Wei TN,
Chen ZZ and Wu WB: CircPAN3 contributes to drug resistance in acute
myeloid leukemia through regulation of autophagy. Leuk Res.
85:1061982019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Liu Y, Dong Y, Zhao L, Su L and Luo J:
Circular RNA-MTO1 suppresses breast cancer cell viability and
reverses monastrol resistance through regulating the TRAF4/Eg5
axis. Int J Oncol. 53:1752–1762. 2018.PubMed/NCBI
|
|
68
|
Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu
Y, Bai YY, Cheng YZ, Nan KJ and Liang X: Autophagy facilitates lung
adenocarcinoma resistance to cisplatin treatment by activation of
AMPK/mTOR signaling pathway. Drug Des Devel Ther. 9:6421–6431.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Jiang B, Yan LJ and Wu Q: ABCB1 (C1236T)
polymorphism affects P-glycoprotein-mediated transport of
methotrexate, doxorubicin, actinomycin D, and etoposide. DNA Cell
Biol. 38:485–490. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huang MS, Yuan FQ, Gao Y, Liu JY, Chen YX,
Wang CJ, He BM, Zhou HH and Liu ZQ: Circular RNA screening from
EIF3a in lung cancer. Cancer Med. 8:4159–4168. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Su Y, Yang W, Jiang N, Shi J, Chen L,
Zhong G, Bi J, Dong W, Wang Q, Wang C and Lin T: Hypoxia-elevated
circELP3 contributes to bladder cancer progression and cisplatin
resistance. Int J Biol Sci. 15:441–452. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ping L, Jian-Jun C, Chu-Shu L, Guang-Hua L
and Ming Z: High circ_100053 predicts a poor outcome for chronic
myeloid leukemia and is involved in imatinib resistance. Oncol Res.
Feb 14–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Joseph NA, Chiou SH, Lung Z, Yang CL, Lin
TY, Chang HW, Sun HS, Gupta SK, Yen L, Wang SD and Chow KC: The
role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR
resistance and epithelial-to-mesenchymal transition of lung
adenocarcinoma cells. J Hematol Oncol. 11:742018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kotmakçı M, Çetintaş VB and Kantarcı AG:
Preparation and characterization of lipid nanoparticle/pDNA
complexes for STAT3 downregulation and overcoming chemotherapy
resistance in lung cancer cells. Int J Pharm. 525:101–111. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Garofalo M and Croce CM: MicroRNAs as
therapeutic targets in chemoresistance. Drug Resist Updat.
16:47–59. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sang Y, Chen B, Song X, Li Y, Liang Y, Han
D, Zhang N, Zhang H, Liu Y, Chen T, et al: circRNA_0025202
regulates tamoxifen sensitivity and tumor progression via
regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther.
27:1638–1652. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Reshke R, Taylor JA, Savard A, Guo H, Rhym
LH, Kowalski PS, Trung MT, Campbell C, Little W, Anderson DG and
Gibbings D: Reduction of the therapeutic dose of silencing RNA by
packaging it in extracellular vesicles via a pre-microRNA backbone.
Nat Biomed Eng. 4:52–68. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liang Y, Song X, Li Y, Su P, Han D, Ma T,
Guo R, Chen B, Zhao W, Sang Y, et al: circKDM4C suppresses tumor
progression and attenuates doxorubicin resistance by regulating
miR-548p/PBLD axis in breast cancer. Oncogene. 38:6850–6866. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yang W, Gu J, Wang X, Wang Y, Feng M, Zhou
D, Guo J and Zhou M: Inhibition of circular RNA CDR1as increases
chemosensitivity of 5-FU-resistant BC cells through up-regulating
miR-7. J Cell Mol Med. 23:3166–3177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yu W, Peng W, Sha H and Li J:
Hsa_circ_0003998 promotes chemoresistance via modulation of miR-326
in lung adenocarcinoma cells. Oncol Res. 27:623–628. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shang J, Chen WM, Wang ZH, Wei TN, Chen ZZ
and Wu WB: CircPAN3 mediates drug resistance in acute myeloid
leukemia through the miR-153-5p/miR-183-5p-XIAP axis. Exp Hematol.
70:42–54.e3. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kun-Peng Z, Xiao-Long M, Lei Z, Chun-Lin
Z, Jian-Ping H and Tai-Cheng Z: Screening circular RNA related to
chemotherapeutic resistance in osteosarcoma by RNA sequencing.
Epigenomics. 10:1327–1346. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Liu F, Zhang J, Qin L, Yang Z, Xiong J,
Zhang Y, Li R, Li S, Wang H, Yu B, et al: Circular RNA EIF6
(hsa_circ_0060060) sponges miR-144-3p to promote the
cisplatin-resistance of human thyroid carcinoma cells by autophagy
regulation. Aging (Albany NY). 10:3806–3820. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Gao D, Qi X, Zhang X, Fang K, Guo Z and Li
L: hsa_circRNA_0006528 as a competing endogenous RNA promotes human
breast cancer progression by sponging miR-7-5p and activating the
MAPK/ERK signaling pathway. Mol Carcinog. 58:554–564. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zhou Y, Zheng X, Xu B, Chen L, Wang Q,
Deng H and Jiang J: Circular RNA hsa_circ_0004015 regulates the
proliferation, invasion, and TKI drug resistance of non-small cell
lung cancer by miR-1183/PDPK1 signaling pathway. Biochem Biophys
Res Commun. 508:527–535. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hua X, Sun Y, Chen J, Wu Y, Sha J, Han S
and Zhu X: Circular RNAs in drug resistant tumors. Biomed
Pharmacother. 118:1092332019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Xiong W, Ai YQ and Li YF, Ye Q, Chen ZT,
Qin JY, Liu QY, Wang H, Ju YH, Li WH and Li YF: Microarray analysis
of circular RNA expression profile associated with
5-fluorouracil-based chemoradiation resistance in colorectal cancer
cells. Biomed Res Int. 2017:84216142017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T and
Zhang L: Analyzing the interactions of mRNAs and ncRNAs to predict
competing endogenous RNA Networks in osteosarcoma Chemo-Resistance.
Mol Ther. 27:518–530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Chi BJ, Zhao DM, Liu L, Yin XZ, Wang FF,
Bi S, Gui SL, Zhou SB, Qin WB, Wu DM and Wang SQ: Downregulation of
hsa_circ_0000285 serves as a prognostic biomarker for bladder
cancer and is involved in cisplatin resistance. Neoplasma.
66:197–202. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wu G, Sun Y, Xiang Z, Wang K, Liu B, Xiao
G, Niu Y, Wu D and Chang C: Preclinical study using circular RNA 17
and micro RNA 181c-5p to suppress the enzalutamide-resistant
prostate cancer progression. Cell Death Dis. 10:372019. View Article : Google Scholar : PubMed/NCBI
|
